RFK Jr. and the Future of Peptide Compounding: What the FDA's Category 2 Review Means for Research

# RFK Jr. and the Future of Peptide Compounding: What the FDA's Category 2 Review Means for Research

Category: Regulatory Updates Read time: 7 min Published: February 28, 2026

On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. made a statement that sent shockwaves through the peptide research and compounding pharmacy communities: approximately 14 of the 19 peptides currently on the FDA's Category 2 bulk drug substance compounding restriction list could be legally compounded again by U.S. pharmacies within a matter of weeks.

This announcement represents one of the most significant regulatory shifts in the peptide space in years — and it has direct implications for researchers, compounding pharmacies, and the broader scientific community studying these compounds.

Background: The FDA's Category 2 Compounding Restrictions

To understand the significance of this announcement, it helps to understand how the FDA's compounding framework works. Under the Drug Quality and Security Act (DQSA) of 2013, the FDA established a process for evaluating bulk drug substances used in compounding. Substances are placed into one of three categories:

- Category 1: Nominated substances that may be used in compounding while under review - Category 2: Substances that the FDA has determined present "significant safety risks" and cannot be used in compounding - Category 3: Substances that have not been nominated or are not eligible for compounding

The 19 peptides placed on the Category 2 list in 2023 and 2024 were effectively banned from compounding pharmacies — meaning they could not be legally prescribed by physicians or dispensed by licensed pharmacies in the United States. This list includes many of the most widely researched peptides in preclinical and clinical literature.

The 19 Compounds on the FDA's Category 2 List

The following compounds were placed on the FDA's Category 2 compounding restriction list:

| Compound | Primary Research Area | |---|---| | BPC-157 | Tissue repair, gut health, angiogenesis | | Cathelicidin LL-37 | Antimicrobial, wound healing | | Emideltide (DSIP) | Sleep regulation, stress response | | Epitalon | Telomere biology, anti-aging | | GHK-Cu (injectable) | Skin regeneration, wound healing | | GHRP-2 (injectable/nasal) | Growth hormone secretion | | GHRP-6 | Growth hormone secretion, appetite | | Ipamorelin acetate | Growth hormone secretion | | Kisspeptin-10 | Reproductive endocrinology | | KPV | Anti-inflammatory, gut health | | Melanotan II | Pigmentation, sexual function research | | PEG-MGF | Muscle repair, angiogenesis | | MOTS-C | Metabolic regulation, mitochondrial function | | Semax | Neuroprotection, cognitive function | | Thymosin beta-4 fragment (LKKTETQ) | Tissue repair, immune modulation | | AOD-9604 | Metabolic research, fat metabolism | | CJC-1295 | Growth hormone secretion | | Selank acetate (TP-7) | Anxiolytic, cognitive enhancement | | Thymosin-alpha 1 (Ta1) | Immune modulation |

What RFK Jr. Actually Said

Secretary Kennedy's statement, made on February 27, 2026, indicated that the HHS and FDA are actively reviewing the Category 2 designations and that approximately 14 of the 19 compounds are expected to be moved off the restricted list — allowing compounding pharmacies to legally prepare and dispense them again under physician supervision.

The five compounds most likely to remain on the restricted list, according to regulatory analysts, are those with the most documented adverse event data or the weakest human safety profiles in FDA's risk assessment: Melanotan II, Cathelicidin LL-37, GHRP-2, Ipamorelin acetate, and CJC-1295 — though the final determination has not been officially published as of this writing.

What This Means for the Research Community

This regulatory shift has several important implications for researchers working with these compounds:

Increased legitimate access through compounding pharmacies. If the FDA removes these compounds from Category 2, licensed compounding pharmacies will once again be able to prepare them for patients under physician prescription. This creates a legitimate, regulated supply chain that did not exist when these compounds were banned.

Research-grade supply remains a distinct category. It is critical to understand that the compounding pharmacy framework — which requires a physician prescription and is intended for therapeutic use — is entirely separate from the research-grade supply framework. Research institutions, laboratories, and academic researchers who use these compounds for in vitro and preclinical studies operate under different regulatory guidelines. Research-grade peptides supplied for laboratory purposes are not subject to the same compounding restrictions.

Quality verification becomes more important, not less. As more compounds re-enter the legal compounding market, the importance of third-party verified quality becomes paramount. Researchers and clinicians alike need to be able to verify the purity, identity, and potency of any compound they work with. Certificate of Analysis documentation from independent laboratories remains the gold standard for establishing compound integrity.

The regulatory landscape will continue to evolve. This announcement represents a directional shift, not a final determination. Researchers should monitor FDA Federal Register notices for official rulemaking and consult legal counsel regarding the specific regulatory status of any compound they work with.

The Distinction Between Compounding and Research Supply

One of the most important points for researchers to understand is the clear distinction between two separate regulatory frameworks:

Compounding pharmacy supply is regulated under the DQSA and requires a valid physician prescription. Compounds dispensed through compounding pharmacies are intended for therapeutic use in identified patients. The Category 2 restrictions apply specifically to this framework.

Research-grade supply for in vitro laboratory use operates under a different framework. Compounds supplied exclusively for laboratory research — not for human or animal therapeutic use — are not subject to the same compounding restrictions. Research institutions use these compounds to study mechanisms of action, conduct preclinical safety assessments, and develop the scientific foundation that informs future clinical research.

Pure Pharm Peptides supplies research-grade compounds exclusively for in vitro laboratory and scientific research purposes. All products are accompanied by third-party Certificate of Analysis documentation verifying purity and identity. Our products are not intended for human or animal consumption, diagnosis, treatment, or prevention of any disease or condition.

Looking Ahead

The RFK Jr. announcement signals a broader shift in how the current administration views peptide research and access. Whether driven by a desire to expand patient access to emerging therapies, reduce regulatory burden on compounding pharmacies, or respond to growing scientific interest in these compounds, the directional movement is toward greater availability — not less.

For the research community, this is a meaningful development. Greater legitimate access through compounding pharmacies means more clinical data, more peer-reviewed research, and ultimately a stronger scientific foundation for understanding these compounds. That benefits everyone working in this space.

We will continue to monitor regulatory developments and update this article as official FDA guidance is published.

This article is provided for informational and educational purposes only. It does not constitute legal advice. Researchers and clinicians should consult qualified legal counsel regarding the regulatory status of specific compounds in their jurisdiction. All Pure Pharm Peptides products are supplied exclusively for in vitro laboratory research use and are not intended for human or animal consumption.

Sources:

1. GLP-1 Forum: "RFK Jr. says ~14 of 19 banned peptides can be legally compounded again by US pharmacies within a few weeks" (February 27, 2026)
2. FDA Drug Quality and Security Act (DQSA), 21 U.S.C. § 503A, 503B
3. FDA Category 2 Bulk Drug Substances List (2023–2024)
4. STAT News: "BPC-157: The peptide with big claims and scant evidence" (February 3, 2026)
5. PeptideLaws.com: "Peptide Regulatory News" (February 2026)